Pipeline PotentialPipeline programs such as zipalertinib and CLN-049 have the potential to meaningfully contribute to Cullinan’s valuation given that the stock trades slightly below cash on hand.
Product EfficacyZipalertinib-treated patients in REZILIENT2 demonstrated a 30% ORR, median DoR of 7.75 months and a disease control rate of 70%, which is compelling evidence of zipalertinib activity in EGFR non-ex20ins patients.
Regulatory MilestonesCullinan is eligible to receive an additional $130M in regulatory milestones in connection with the agreement.